FindTrial
Sign In

Phase 3, multicenter, double-blind, parallel-group study to evaluate the efficacy and safety of TAK-085 in subjects with hypertriglyceridemia

Phase 3, multicenter, double-blind, parallel-group study to evaluate the efficacy and safety of TAK-085 in subjects with hypertriglyceridemia

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220905
Enrollment
Unknown
Registered
2009-10-29
Start date
2009-10-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia

Interventions

investigational material(s) Generic name etc : TAK-085 INN of investigational material : Therapeutic category code : 218 Agents for hyperlipidemias Dosage and Administration for Investigational mater

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects diagnosed with hypertriglyceridemia, etc.

Exclusion criteria

Exclusion criteria: 1. Subject had coronary artery disease 2. Subject received aortic aneurysmectomy 3. Subject had hemorrhagic disease etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026